Mineralys Therapeutics, Inc.

US$15.33As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:MLYSHealthcare
Country USA
PE (Fwd) •••
TSR 4Y CAGR (3.93%)
Div yield —
ROE (68.50%)
Biotechnology
Beta (5Y) 0.83
PE TTM —
TSR TTM (62.48%)
Mkt cap US$1.358B
ROIC (41.34%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$16
1.69%
(98.22%)
Hold 5|6|1|9|5
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.25
0.27
0.30
0.32
15.39%
34.05%
39.21%
37.10%
Revenue$M
103.1
102.7
103.3
108.2
5.09%
0.57%
(3.12%)
4.34%
Peers (US$1.358B)
Cap (US$)
PE
1.389B
6.637x
1.358B
7.510x
Capital
TTM
5Y
10Y
Leveragex
0.613
0.098
0.084
EBIT/Intx
0.605
0.085
0.097
Own earn%
(110.32)
(53.57)
(80.33)
Sh yield%
37.30
33.10
26.09
Owners
Insiders/Inst%
10.63
59.85
Short interest%
5.81
SBC / revenue%
4.69
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
0
Op margin range%
8–15
$1 testx
—
Incr. ROIC%
9